MedTrace Logo

Female Autologous Platelet-Rich Plasma (PRP) Co-incubation With Husband's Sperm

NCT07282327 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 288

Last updated 2025-12-15

No results posted yet for this study

Summary

Hypotheses:

We hypothesize that infertility patients undergoing IUI who receive female autologous platelet-rich plasma (PRP) co-incubation with husband's sperm would have higher clinical pregnancy rate.

Aims:

* To determine if the use of female autologous platelet-rich plasma (PRP) co-incubation with husband's sperm in the IUI will show higher clinical pregnancy rate (CPR). Clinical pregnancy rate as determined by a positive serum beta-hCG test result and at least one gestational sac at 6 weeks gestation
* To assess the safety of female PRP co-incubation with husband's sperm in the IUI.

Primary outcome:

To compare the incidence of clinical pregnancy outcome in those infertility patients undergoing IUI with female PRP co-incubation with husband's sperm group and non-PRP group.

Secondary outcomes:

* To evaluate the safeness between the female PRP co-incubation with husband's sperm in the IUI group and non-PRP group, including potential infection rate or other complications such as ectopic pregnancy and molar pregnancy
* To evaluate the sperm quality between the intervention group and control group

Data analysis: Data analysis will be performed using Statistical Packages of Social Sciences for Windows

Expected results: The investigators expect that a 50% pregnancy rate increase after the application of female PRP co-incubation with husband's sperm in the IUI

Conditions

  • Reproductive Issues

Interventions

OTHER

Female PRP co-incubation with husband's sperm in the IUI

Intervention group (Female PRP co-incubation with husband's sperm in the IUI)

OTHER

Sham Comparator: Control group

Control group (non-PRP in the conventional IUI)

Sponsors & Collaborators

  • Chinese University of Hong Kong

    lead OTHER

Principal Investigators

  • Jacqueline Pui Wah Chung · Chinese University of Hong Kong

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
42 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-10
Primary Completion
2027-02-28
Completion
2027-08-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07282327 on ClinicalTrials.gov